Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01064622 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

NIH

Sponsor class

Conditions

Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

DRUG: Gemcitabine Hydrochloride
OTHER: Hydrocortisone/Placebo
DRUG: Vismodegib

Sponsor

National Cancer Institute (NCI)